Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Lilly, Amylin Resubmit Bydureon Application

By Drug Discovery Trends Editor | July 29, 2011

INDIANAPOLIS (AP) – Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said they have resubmitted to the Food and Drug Administration their application for a longer-lasting version of the diabetes treatment Byetta, and they expect the review to take up to six months.

The companies received European approval last month for the drug, labeled Bydureon, which is designed to be taken once a week. It is currently available in the United Kingdom.

Byetta, or exenatide, is taken twice a day and has been on the market for several years. Lilly, based in Indianapolis, and Amylin, headquartered in San Diego, are developing Bydureon along with Alkermes Inc. of Waltham, Mass. Alkermes created the technology that gradually releases the drug over the course of a week.

Last fall, the FDA declined to approve Bydureon and asked the companies to run a thorough study that evaluated effects of bigger doses of Bydureon on patient heart rates.

The companies said their reply contained results from the requested study, updated safety information and results from a study comparing Bydureon to Byetta.

In March, the companies said Bydureon proved inferior to Novo Nordisk’s Victoza according to initial results from a late-stage study. They said Bydureon reduced average blood sugar levels in type 2 diabetes patients by a smaller amount from a baseline measurement than Victoza. The study compared Bydureon with a maximum approved dose of 1.8 milligrams of Victoza administered daily.

Date: July 28, 2011
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE